IN8bio (NASDAQ:INAB) Upgraded at Zacks Research

Zacks Research upgraded shares of IN8bio (NASDAQ:INAB) to a hold rating in a report published on Thursday morning,Zacks.com reports.

Several other research firms also recently commented on INAB. Mizuho set a $4.00 price objective on IN8bio in a report on Monday, October 13th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $92.00.

IN8bio Price Performance

Shares of INAB opened at $2.59 on Thursday. The firm’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $2.08. The company has a market capitalization of $10.93 million, a P/E ratio of -0.47 and a beta of -0.01. IN8bio has a 1-year low of $1.17 and a 1-year high of $12.53.

IN8bio (NASDAQ:INAB) last announced its earnings results on Thursday, November 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.35. On average, equities analysts anticipate that IN8bio will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Stonepine Capital Management LLC purchased a new position in IN8bio during the second quarter valued at approximately $172,000. Two Sigma Investments LP purchased a new position in shares of IN8bio in the third quarter worth about $107,000. Finally, Citadel Advisors LLC purchased a new stake in shares of IN8bio in the 3rd quarter valued at $54,000. Institutional investors own 92.05% of the company’s stock.

More IN8bio News

Here are the key news stories impacting IN8bio this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts substantially — Q1–Q4 2026 estimates were moved from roughly ($1.20)/($1.50) per quarter to about ($0.21), ($0.25), ($0.29) and ($0.33) respectively, implying materially lower expected losses in 2026 versus the firm’s prior views. HC Wainwright raises near-term EPS estimates
• Positive Sentiment: Annual estimates were also upgraded: FY2025 EPS was revised to ($0.66) and FY2026 to ($1.09) from much larger prior negatives (HC previously forecast FY2026 around ($5.71)), signaling the analyst now expects significantly less downside than before. HC Wainwright upgrades FY2025–FY2026 forecasts
• Positive Sentiment: HC Wainwright laid out a multi-year path to profitability, forecasting FY2029 EPS of $0.25 and FY2030 EPS of $0.62 — a signal that the analyst expects long-term commercialization or margin improvement that could materially change IN8bio’s earnings profile. HC Wainwright projects FY2029–FY2030 profitability
• Neutral Sentiment: Despite upgrades, HC’s FY2026 forecast (-$1.09) remains below the consensus full-year estimate of ($0.56), so analyst views are improving but not fully aligned with market consensus; timing and execution risk remain. Comparison to consensus estimates
• Negative Sentiment: The company is still forecast to be loss-making through the mid-2020s under HC’s model, and its small market cap and historical volatility mean upgrades can spark short-term moves but don’t remove execution, clinical and financing risk. Investors should treat the revisions as improving optimism rather than proof of sustained profitability. Risk and context

IN8bio Company Profile

IN8bio, Inc (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications.